Table 1.
Frequency of clinical or laboratory abnormalities in the 120 child and adolescent users of risperidone assessed by the study.
| Abnormalities | n (%) |
|---|---|
| Overweight | 32 (26.7) |
| Obese | 5 (4.2) |
| Diabetes mellitus | 0 |
| BP∗ | 8 (6.7) |
| Metabolic syndrome | 6 (5) |
| Increased waist circumference§ | 20 (16.7) |
| HOMA-IR changes | 22 (18.3) |
| Total hypercholesterolemia | 32 (26.7) |
| Hypercholesterolemia | 29 (24.2) |
| Hypocholesterolemia | 40 (33.3) |
| Hypertriglyceridemia | 41 (34.2) |
BP, blood pressure; HOMA-IR, homeostatic model assessment of insulin resistance.
∗16 (13.3%) subjects were classified as prehypertensive; §44 (36.7%) subjects were classified as being between the 75th and 90th percentiles for waist circumference.